228 related articles for article (PubMed ID: 31201250)
1.
Burke BP; Miranda CS; Lee RE; Renard I; Nigam S; Clemente GS; D'Huys T; Ruest T; Domarkas J; Thompson JA; Hubin TJ; Schols D; Cawthorne CJ; Archibald SJ
J Nucl Med; 2020 Jan; 61(1):123-128. PubMed ID: 31201250
[TBL] [Abstract][Full Text] [Related]
2. 64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.
Jacobson O; Weiss ID; Szajek L; Farber JM; Kiesewetter DO
Bioorg Med Chem; 2009 Feb; 17(4):1486-93. PubMed ID: 19188071
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100.
Weiss ID; Jacobson O; Kiesewetter DO; Jacobus JP; Szajek LP; Chen X; Farber JM
Mol Imaging Biol; 2012 Feb; 14(1):106-14. PubMed ID: 21347799
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of N-[(11)C]methyl-AMD3465 as a PET tracer for imaging of CXCR4 receptor expression in a C6 glioma tumor model.
Hartimath SV; van Waarde A; Dierckx RA; de Vries EF
Mol Pharm; 2014 Nov; 11(11):3810-7. PubMed ID: 25094028
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of [
Peng T; Wang X; Li Z; Bi L; Gao J; Yang M; Wang Y; Yao X; Shan H; Jin H
Mol Pharm; 2021 Sep; 18(9):3638-3648. PubMed ID: 34424706
[TBL] [Abstract][Full Text] [Related]
6. Bridged cyclams as imaging agents for chemokine receptor 4 (CXCR4).
Woodard LE; De Silva RA; Behnam Azad B; Lisok A; Pullambhatla M; G Lesniak W; Mease RC; Pomper MG; Nimmagadda S
Nucl Med Biol; 2014 Aug; 41(7):552-61. PubMed ID: 25038987
[TBL] [Abstract][Full Text] [Related]
7. CXCR4-targeted PET imaging using
Muz B; Bandara N; Mpoy C; Sun J; Alhallak K; Azab F; Rogers BE; Azab AK
Cancer Biol Ther; 2020; 21(1):52-60. PubMed ID: 31571524
[No Abstract] [Full Text] [Related]
8. Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465.
De Silva RA; Peyre K; Pullambhatla M; Fox JJ; Pomper MG; Nimmagadda S
J Nucl Med; 2011 Jun; 52(6):986-93. PubMed ID: 21622896
[TBL] [Abstract][Full Text] [Related]
9. Development and Evaluation of an
Brickute D; Braga M; Kaliszczak MA; Barnes C; Lau D; Carroll L; Stevens E; Trousil S; Alam IS; Nguyen QD; Aboagye EO
Mol Pharm; 2019 May; 16(5):2106-2117. PubMed ID: 30883140
[TBL] [Abstract][Full Text] [Related]
10. Imaging CXCR4 Expression with Iodinated and Brominated Cyclam Derivatives.
Zhang H; Maeda M; Shindo M; Ko M; Mane M; Grommes C; Weber W; Blasberg R
Mol Imaging Biol; 2020 Oct; 22(5):1184-1196. PubMed ID: 32239371
[TBL] [Abstract][Full Text] [Related]
11. In vivo validation of
Renard I; Domarkas J; Poty S; Burke BP; Roberts DP; Goze C; Denat F; Cawthorne CJ; Archibald SJ
Nucl Med Biol; 2023; 120-121():108335. PubMed ID: 37068392
[TBL] [Abstract][Full Text] [Related]
12.
Alzahrani SO; McRobbie G; Khan A; D'huys T; Van Loy T; Walker AN; Renard I; Hubin TJ; Schols D; Burke BP; Archibald SJ
Dalton Trans; 2024 Mar; 53(12):5616-5623. PubMed ID: 38439632
[TBL] [Abstract][Full Text] [Related]
13. Importance of receptor flexibility in binding of cyclam compounds to the chemokine receptor CXCR4.
Lam AR; Bhattacharya S; Patel K; Hall SE; Mao A; Vaidehi N
J Chem Inf Model; 2011 Jan; 51(1):139-47. PubMed ID: 21158459
[TBL] [Abstract][Full Text] [Related]
14. Second generation Al
Spahn MA; Luyten K; Van Loy T; Sathekge M; Deroose CM; Koole M; Schols D; Vanduffel W; De Vos K; Annaert P; Bormans G; Cleeren F
Nucl Med Biol; 2024; 132-133():108906. PubMed ID: 38518400
[TBL] [Abstract][Full Text] [Related]
15. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
[TBL] [Abstract][Full Text] [Related]
16. [
Amor-Coarasa A; Kelly J; Ponnala S; Vedvyas Y; Nikolopoulou A; Williams C; Jin MM; David Warren J; Babich JW
Nucl Med Biol; 2018 May; 60():37-44. PubMed ID: 29544122
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator.
Wei L; Butcher C; Miao Y; Gallazzi F; Quinn TP; Welch MJ; Lewis JS
J Nucl Med; 2007 Jan; 48(1):64-72. PubMed ID: 17204700
[TBL] [Abstract][Full Text] [Related]
18. PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates.
Beaino W; Anderson CJ
J Nucl Med; 2014 Nov; 55(11):1856-63. PubMed ID: 25256059
[TBL] [Abstract][Full Text] [Related]
19. Exploring pitfalls of
Striese F; Sihver W; Gao F; Bergmann R; Walther M; Pietzsch J; Steinbach J; Pietzsch HJ
Amino Acids; 2018 Oct; 50(10):1415-1431. PubMed ID: 30039310
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.
Kumar SR; Gallazzi FA; Ferdani R; Anderson CJ; Quinn TP; Deutscher SL
Cancer Biother Radiopharm; 2010 Dec; 25(6):693-703. PubMed ID: 21204764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
